UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (date of earliest event reported): December 21, 2006
 
ZIOPHARM Oncology, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
0-32353
 
84-1475642
 
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

 
1180 Avenue of the Americas, 19th Floor
New York, NY 10036
(Address of principal executive offices) (Zip Code)
 
(646) 214-0700
(Registrant’s telephone number, including area code)
 
 
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 1.01. Entry into a Material Definitive Agreement.

On January 8, 2004, ZIOPHARM Oncology, Inc. (the “Company”) entered into a three year employment agreement with Dr. Jonathan Lewis, pursuant to which Dr. Lewis is serving a Chief Executive Officer of the Company until January 8, 2007. On December 21, 2006, the Company and Dr. Lewis entered into an Employment Agreement Extension (the “Extension”). Pursuant to the Extension, the Company extended the term of Dr. Lewis’ employment to January 8, 2008 and increased Dr. Lewis’ annual base salary to $385,000.

A copy of the Extension is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits. The following exhibit is furnished herewith.

Exhibit No.
Description
   
10.1
 
Employment Agreement Extension dated December 21, 2006
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
   
  ZIOPHARM Oncology, Inc.:
  (Registrant) 
 
 		  
 		  
 
Date: December 26, 2006  By:   /s/ Richard E. Bagley 
 
Richard E. Bagley, President,
Chief Operating Officer and Chief Financial Officer
   


 


Exhibit Index

Exhibit No.
Description
   
 
10.1
 
 
Employment Agreement Extension dated December 21, 2006